CompletedACTRN12617000002381
Official study titleAn open label, two-way crossover study to evaluate the absolute bioavailability of BnoX Trademark, a novel sublingual wafer formulation of buprenorphine, in healthy volunteers under fasted conditions.
This study has finished and is no longer accepting participants.
In AustraliaAddictionInterventional studyAges 18–65
- Countries
- Australia
- Sponsor
- iX Biopharma Pty Ltd
CompletedNCT01926912
Official study titleHOSPItal Use of Paliperidone Palmitate - A Prospective Non-Interventional Study
This study has finished and is no longer accepting participants.
Multiple locations, including DiestSchizophreniaObservational studyAges 18+
- Countries
- Belgium, Bulgaria, Denmark, + 5 others
- Sponsor
- Janssen-Cilag International NV
CompletedNCT00621777
About this title
A Study of Varenicline for Prevention of Relapse to Smoking in Patients With Schizophrenia or Bipolar Disorder
Read the official source — NCT00621777Official study titleExtended Duration Pharmacotherapy for Prevention of Relapse to Smoking
This study has finished and is no longer accepting participants.
Multiple locations, including BirminghamBipolarity, SchizophreniaMedication studyAges 18–70
- Countries
- United States
- Sponsor
- Massachusetts General Hospital (Hospital / academic medical center)
CompletedNCT00645320
About this title
A Study of Ziprasidone for the Treatment of Psychosis in Patients Who Had Already Had Benefits From Ziprasidone Treatment in a Previous Study
Read the official source — NCT00645320Official study titleAn Open Label, Extension Study To Assess The Efficacy And Tolerability Of Oral Ziprasidone In Patients Successfully Completing A Previous Study With Ziprasidone
This study has finished and is no longer accepting participants.
Multiple locations, including RIO de Janeiro RJSchizophreniaMedication studyAges 18–55
- Countries
- Brazil
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
CompletedNCT00363376
About this title
A Study of Zonisamide to Prevent Olanzapine-Associated Weight Gain
Read the official source — NCT00363376Official study titleA Double-Blind, Placebo-Controlled Study of Zonisamide to Prevent Olanzapine-Associated Weight Gain
This study has finished and is no longer accepting participants.
In MasonBipolarityMedication studyAges 18+
- Countries
- United States
- Sponsor
- Lindner Center of HOPE
CompletedNCT04132557
Official study titleSuicidality, Psychosis or Substance Abuse With Methylphenidate, Atomoxetine, Amphetamine/Dextroamphetamine or Lisdexamfetamine, a Post-authorization Safety Study
This study has finished and is no longer accepting participants.
In TitusvilleSuicidality, SchizophreniaObservational study
- Countries
- United States
- Sponsor
- Janssen Research & Development, LLC
CompletedNCT05039489
This study has finished and is no longer accepting participants.
In ChangshaSchizophreniaMedication studyAges 18–45
- Countries
- China
- Sponsor
- Central South University
Active Not RecruitingNCT06744751
Official study titleA Randomsized Controlled Study on the Effects of Combined Fecal Microbiota Transplantation on Gut Microbiota and Eating Disorder Symptoms in Patients With Anorexia Nervosa
This study is no longer accepting new participants.
In ShanghaiEating disordersPlacebo comparisonAges 12–35
- Countries
- China
- Sponsor
- Shanghai Mental Health Center
UnknownNCT02234076
Current recruitment status is unconfirmed.
Multiple locations, including 's-HertogenboschPTSD, DepressionBehavioural studyAges 18–70
- Countries
- Netherlands
- Sponsor
- Erasmus Medical Center
CompletedNCT01932398
Official study titlePosterior Alpha Oscillations as an Index for the Attentional Bias in Children With Attentional Deficit Hyperactivity Disorder
This study has finished and is no longer accepting participants.
In NijmegenADHDObservational studyAges 84–95 months
- Countries
- Netherlands
- Sponsor
- Radboud University Medical Center
UnknownNCT06005779
Official study titleAn Ambispective Cohort Study on the Prognosis and Its Influencing Factors of Borderline Personality Disorder
Current recruitment status is unconfirmed.
In WuhanPersonality disordersObservational studyAges 12+
- Countries
- China
- Sponsor
- Wuhan Mental Health Centre
UnknownNCT06657430
Current recruitment status is unconfirmed.
In ShanghaiSchizophrenia, BipolarityObservational studyAges 18+
- Countries
- China
- Sponsor
- Shanghai Mental Health Center